The tech sector is booming with Apple's record iPhone sales and Amazon's surge fueled by AI, though Meta faces challenges with AI investment costs and OpenAI faces regulatory scrutiny, alongside diverse performance across other digital and media companies and growing robotic integration in cities.
Across various industries, companies report mixed financial results, with ANZ Bank facing a significant profit hit while Mastercard shows strong consumer spending, and notable **M&A activity includes Onex and AIG's acquisition of Convex and Lukoil selling international assets due to sanctions**.
A one-year trade truce between the US and China offers temporary relief to soybean farmers and eases rare earth export controls, despite underlying tensions and investor skepticism about a lasting accord, impacting automakers like Volkswagen and Hyundai.
The pharmaceutical sector sees intense competition as **Novo Nordisk bids $9 billion for Metsera to challenge Pfizer in obesity drugs, while Eli Lilly, Biogen, Bristol Myers Squibb, and Merck report strong earnings driven by demand for new and flagship treatments, and the FDA aims to speed up approvals for cheaper biosimilar drugs**.
Central banks like the ECB and Bank of Japan maintain steady interest rates, while the Federal Reserve considers reducing banking supervision staff and acknowledges economic uncertainty from government shutdowns, with Argentina's new leader plotting significant economic overhauls and discussions on UK spending cuts.